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Measuring renal function in pediatric patients is a necessity due to numerous infectious and non-
infectious diseases that may result in renal dysfunction. As many therapies include pharmaceuticals 
with renal elimination, the renal function must also be evaluated for the dosage of these 
pharmaceuticals. Thus overall, a reliable as well as simple and fast renal diagnostic is of great 
value for a general practitioner as well as specialists in pediatric nephrology, cardiology or oncology 
among others. 
The glomerular filtration rate (GFR) serves as a reliable parameter of the renal function. It is 
measured in milliliters of blood plasma filtered by the glomeruli per minute and adjusted to the body 
surface area (ml/min/1.73m²). The GFR may be evaluated by the urinary clearance of a substance 
“x” and is measured in [ml/min]. ⁠1 It indicates the plasma volume that is theoretically cleared from a 
certain substance “x” in one minute and is estimated by the functional relationship: 
Cx=Ux · V/Px 
where Cx is the clearance, Ux  the concentration of x in the urine, V  the milliliters of urine per minute, 
and Px the concentration of x in the plasma. 
Technically advanced methods 
The inulin clearance is one gold standard established in renal diagnostic. Inulin is freely filtered in 
the glomeruli and undergoes neither tubular nor extra-renal secretion.⁠2 However, current 
recommendations suggest three sampling times, the first one no earlier than 90 minutes after inulin 
infusion. Especially in patients with renal function impairment, a delayed sampling is necessary, as 
precipitate samples will lead to GFR overestimation.⁠3,4 Thus, this diagnostic is very time-consuming, 
impractical especially in clinical settings, and it strains the patience particularly of small children. 
An equivalent alternative is the measurement of GFR using radioisotopes. Renal function is 




Furthermore, radioisotopes are bound by plasma proteins leading to GFR underestimation of about 
ten percent compared to inulin.⁠5 
Finally, computer tomography may be used to determine renal function. The administration of the 
iod-compound iothalamate only requires one injection and no further blood nor urine samples. 
Nevertheless, radiation once more limits this method. Additionally, iothalamate undergoes tubular 
secretion leading to an overestimation of GFR.⁠6  
Serum creatinine 
Methods using this endogenous marker are standards in daily renal diagnostics. Besides the 
MDRD formula used particularly in adults, the Schwartz formula is most often applied to pediatric 
patients. It considers the serum concentration of creatinine (sCrea) as well as the body height. ⁠7 
The height is taken into account because of the inter- and intra-patient variability of sCrea related 
to varying body stature and muscle mass.⁠8  
GFR = 0.413 x height/sCrea(mg/dl)⁠9  
To make up for the gain of muscle mass in puberty, equations including gender-depending factors 
during puberty are necessary. Additionally, several GFR equations consider the body surface area 
as denominator to diminish that effect.10 Furthermore, in patients with spina bifida, neuromuscular 
diseases, liver cirrhosis or anorexia nervosa sCrea is unable to be used as the muscle mass is 
decreased (especially in patients bound to a wheelchair).11 Besides its glomerular filtration, 
creatinine is also secreted by the proximal tubules, leading to an over-estimation of the GFR, 
especially in patients with mild renal impairment.12  
Serum Cystatin C 
A promising new endogenous marker for renal function is Cystatin C (CysC), a cysteine protease 
inhibitor and low molecular weight protein.13 As a product of a housekeeping gene, it is produced 
by all human nucleated cells at a stable production rate.14 Therefore, CysC seems to be unaffected 
by body muscle mass and growth. CysC is freely filtered in the glomeruli and shows 94-99% of the 
plasma clearance measured by the GFR-marker 51Cr-EDTA.15,16 At least 99% of the glomerular 




appearing in the urine.16 More features of CysC including the physicochemical properties were 
reviewed by Filler, Bokenkamp et al.⁠1: Its molecular mass accounts to 13,343 Da, although 50% of 
the CysC proteins carry an additional hydroxylated proline residue adding to the molecular mass 
of then totally 13,359 Da. Its isoelectric point is 9.3; therefore it is positively charged in almost all 
body fluids. CysC levels are measured using the rapid and precise particle-enhanced turbidimetric 
or nephelometric immunoassays (PETIA and PENIA).17,18 
In adults, CysC is already well established in renal diagnostic routine. It generally correlates higher 
with gold standard methods compared to sCrea: a systematic review in 27 population groups 
(n=2 007)19 as well as a meta-analysis of 46 articles published until 2001 show that overall CysC is 
superior to sCrea.20 Galteau et al. (n= 1 223) showed that CysC levels are 0.74±0.100 mg/l for 
males and 0.65±0.085 mg/l for females aged 20–59 years, independent from intake of 
contraceptives, menopause or hormonal replacement therapy.21  In individuals aged 60 years or 
older, CysC reference values were estimated as 0.83±0.103 mg/l. Those results were confirmed 




Current state of research 
Reference values of Cystatin C 
In 2009, Andersen et al. reviewed several studies and compared CysC levels resulting from 
different applied methods. One year later Andersen stated that CysC was independent of age (n=30, 
age range 2-14 years, p=0.11).22 Ridefelt et al. were able to evaluate the data of a larger group of 
children (n=692). Using the Abbott Architect ci8200, they proposed reference intervals of 0.77-1.09 
for 6-12-month-old and 0.63-1.08 for 1-18-year-old children.23 
Overall, newborns have higher CysC levels. Various studies confirmed physiological 
concentrations of 1.70 ± 0.26 mg/l (PETIA) or 1.97 ± 0.36 mg/l (PENIA).24–27 Pre-term infants have 
higher CysC concentrations of 1.88 mg/l ± 0.36 mg/l (PETIA).28 The concentrations significantly 
decrease two days after birth (1.61 ± 0.37 mg/L on day 3)29 and are neither associated with 
gestational age, birth weight nor maternal renal function.26,29,30 So far, most studies showed that 
CysC concentrations reach steady levels after one to three years of life.25–27,28 CysC levels of  0.72 
± 0.12 mg/L (PENIA) or 0.98 ± 0.20 mg/l (PETIA) respectively were reported independent from age 
and gender.25,28 It remained constant up to the age of 14-16 years, according to some studies even 
up to adulthood.25 Most studies found no effect of gender or age during childhood and 
adolescence.25,26,31 Furthermore, Galteau et al. could not find an association to the hormonal status 
in women or alcohol intake.21  
Nevertheless, Yata et al. were able to collect data from a much larger group of 1128 children. They 
could show that CysC levels decreased at the age of 15-16 years and were higher in males 
compared to females at that same age (see Figure 1 and Figure 2 below).27 Groesbeck et al. 
confirmed that especially in females aged 12-19 years, cystatin C levels decrease (n=719).32  





Cystatin C in healthy test persons 
In contrast to serum Creatinine (sCrea), neonatal CysC concentrations are independent from 
maternal blood levels30,33 and inversely correlate with the GFR of gold standard methods three 
days after birth. Both seem to be unaffected by sex, gestational age, birth weight, bilirubin levels 
and hydration state, but are associated with cord blood pH and hemoglobin level.33 Bokenkamp et 
al. collected data of 258 children without evidence of kidney disease (age range one day to 18 
years). They support the thesis that CysC remains constant after the first year of life, while sCrea 
steadily increases until adulthood due to the gain of muscle mass.34 Comparing sCrea and CysC, 
the reciprocal of sCrea correlated less with the inulin clearance as the gold standard (r=0.72) than 
CysC (r=0.88). Furthermore, the body height was a covariate for sCrea. Further, female gender as 
well as dystrophy were linked to an underestimation of GFR.35  
Validity of Cystatin C for kidney diseases 
In patients with renal diseases, CysC increases the diagnostic sensitivity in contrast to sCrea.36 
Furthermore, when correlated with the creatinine clearance, CysC shows a stronger correlation 
coefficient (r=0.64) than sCrea (r=0.55), but still a lower correlation coefficient than the 
height/creatinine ratio (r=0.73).37 Another study concluded that the creatinine clearance seems to 
be the best estimate of GFR, followed by the Haycock-Schwartz formula followed by CysC and 
finally sCrea (all significantly different from one another).38 Due to the changing muscle mass during 
growth and development, in pediatric patients, the intrapatient variability of sCrea is significantly 
higher when compared to CysC.39,40 Besides, sCrea tends to overestimate renal function most 
notably in females as well as in patients with dystrophy or glomerular diseases.12,35 In order to 
detect especially initial renal failure, CysC is the more sensitive parameter with a furthermore higher 
negative predictive value.41 Overall, this suggests supremacy of CysC over sCrea due to its higher 
diagnostic accuracy. 
CysC is also superior to Creatinine in examining specific kidney diseases. Mussap et al. measured 
amniotic fluid of 95 pregnant women. They found out that CysC levels were elevated in women with 
uropathic fetuses, whereas Creatinine levels showed no significant difference when compared to 




cystatin C as well as ß2-microglobulin were significantly elevated.43 Because of small sample sizes, 
data on pediatric patients with polycystic kidney diseases are nonconclusive and controversial.43 
Post-transplant validity of Cystatin C 
Several studies reviewed the diagnostic value of CysC in post-transplant pediatric patients. When 
correlated with the iothalamate-GFR as the gold standard, CysC showed a higher correlation 
coefficient in post-transplant patients (r=0.83) than sCrea (r=0.67) or the creatinine clearance 
(r=0.57). Nevertheless, its diagnostic accuracy was the same as that of the creatinine clearance. 
At a cut-off value of 1.64 mg/l Risch et al. calculated a positive predictive value of 93%, a specificity 
of 89% and a sensitivity of 70%. Only the sensitivity of the creatinine clearance scored higher with 
85%.44,45 However, Aufricht et al. were not able to confirm CysC as the superior marker.46 Research 
in adult post-transplant patients may help to end this controversy: compared to radiolabeled DTPA 
measuring as the gold standard, CysC equations (especially the equations of Filler and Le Bricon) 
showed less bias and highest accuracy in contrast to sCrea equations. That effect remained the 
same in patients with GFR > 60ml per minute per 1.73m² (87-89% within 30% of measured GFR) 
whereas only 53-80% of Creatinine estimates were within 30% of measured GFR.47  
Overall, considering the high standard deviation of the creatinine clearance of 17.8%, CysC as well 
as CysC-based equations (currently only validated for a GFR between 15-75 ml/min/1.73m²) seem 
to be more suitable markers in post-transplant pediatric patients.48 
Validity of Cystatin C in extra-renal diseases 
In diabetic patients with a stable metabolic status, CysC was significantly decreased compared to 
patients with ketonuria and the superior marker over sCrea when compared to the iohexol 
clearance. The creatinine clearance was furthermore an unreliable marker of GFR.49 CysC was 
also the most accurate diagnostic marker in patients with renal diseases as a result of uropathy 
due to a spina bifida (r=0.45), whereas sCrea and the Schwartz formula showed no correlation with 
GFR.11 A similar effect was found in pediatric cancer patients, where the diagnostic value of CysC 





In 1976, the first Schwartz equation considered only body height and sCrea (0.55xLength/sCrea), 
but is still the most commonly used formula in clinical practice with a single modification in 2009 
(GFR = 0.413 x height/sCrea(mg/dl)).⁠7,9 It showed an excellent agreement with creatinine (r=0.935) 
and inulin clearance (r=0.905).⁠7 The four most common CysC equations were developed by Filler, 
Grubb, Zapitelli and Schwartz.  
Besides CysC concentration, Grubb included a factor for prepubertal children (younger than 14 
years). The equation assessed the GFR at least as well as the creatinine-based Schwartz formula. 
Its prediction performance was apart from the factor for prepubertal children unaffected by age.51 
Grubb: GFR = 84.69 x [CysC]1.680 x 1.384(if a child <14 years) 
Filler et Lepage compared a solely on CysC based equation with the creatinine-based Schwartz 
formula (in contrast to 99mTc DTPA as gold standard). The children (aged 1–18 years, n=536) 
tested had various renal pathologies. The Schwartz formula tended to overestimate the GFR. That 
effect was not found in the CysC-based equation, not even in patients with a lower GFR.52 Two 
years later, Filler et al. confirmed in a similar study design that CysC-based equations resulted in 
the least error.53 
Filler: log(GFR) = 1.962 + [1.123 x log(1/CysC)] 
Zapitelli derived two CysC equations (thereof one combined with sCrea) and compared them to 
iothalamate as the gold standard. Both equations were superior over the Schwartz formula and 
showed less bias and greater precision in transplant patients due to a transplant-factor included in 
each formula.54 
Zapitelli 1: GFR = 75.94 / [CysC]1.17 x 1.2(if renal transplant) 
Zapitelli 2: GFR = (507.76 x e0.003 x	height)/(CysC0.635 x sCrea0.547) x 1.165(if renal transplant) 
Not only Zapitelli, but also Schwartz tried to combine CysC and sCrea in one formula to achieve 
better diagnostic accuracy. The equation based on turbidimetrically measured CysC (2009) yielded 
to 87.7% within 30% of the iohexol GFR whereas the second one based on nephelometrically 




nitrogen (BUN) as an additional nephrodiagnostic parameter and are the only equations validated 
for pediatric patients with a GFR between 15 and 75 ml/min/1.73m². 
Schwartz (turbidimetric): GFR = 39.1 x (height/Scr)0.516 x (1.8/CysC)0.294 x (30/BUN)0.169  
x 1.099 (if male) x (height/1.4)0.188 
Schwartz (nephelometric): GFR = 39.8 x (height/Scr)0.456 x (1.8/ CysC)0.418 x (30/BUN)0.079  
x 1.076 (if male) x (height/1.4)0.179 
Finally, Andersen et al. established and validated a formula based on CysC, sCrea as well as body 
cell mass (BCM) and body surface area (BSA). They assumed that concentration of CysC depends 
on BCM as it is produced by all nucleated cells. Indeed, the formula’s predictive value is higher 
than those of any other equation (98% within ±30% of GFR and 66% within ±10%). Furthermore, 
the weight-based (instead of BCM) equation performed almost as well.56 
Andersen (BCM-based): GFR = 0.542 x (BCM/CysC)0.40 x (height x BSA/sCrea)0.65 
Andersen (weight-based): GFR = 0.426 x (weight/CysC)0.39 x (height x BSA/sCrea)0.64 
Confounders 
A large cross-sectional analysis of 3418 adults including clinical trial participants as well as patients 
with chronic kidney diseases compared CysC and sCrea levels with the urinary clearance of 
iothalamate and creatinine. CysC levels were 4.3% lower for every 20 years of age and 9.2% lower 
in females. The impact of age and gender were even higher on sCrea than on CysC (Figure 3).57 
Another large study with more than 8000 adults showed that age, gender, weight and height as 
well as current cigarette smoking were solely associated with CysC levels.58 No similar associations 
have been found specifically in children yet. 
The hormone balance seems to be linked to CysC serum concentration. Diabetes, for example, is 
associated with ~8.5% higher CysC concentrations, whereas sCrea has ~3.9% lower levels (Figure 
3).57 Besides, CysC levels were significantly elevated in children treated with glucocorticoids for 
malignancy or renal disease, although levels of other low molecular weight proteins were more 




treated with glucocorticoids.60 Additionally, in patients with thyroid dysfunction, CysC levels 
moderately but significantly raise along with thyroxin blood levels.61  
Finally, patients with proteinuria seem to have elevated urinary levels of CysC.62 Higher levels of 
CRP and white blood cells as well as lower serum albumin concentrations are associated with 
elevated concentrations of CysC, but lower levels of sCrea.58,59,63 After adjustment for creatinine 
clearance, CysC was furthermore shown to be higher with older age, male gender, higher weight, 




Relevance of the topic 
Urinary and renal infections are very frequent diseases.64 Besides, the overall prevalence of renal 
anomalies accounts up to 0.1%.65 This already points out the importance of reliable as well as fast 
and convenient renal diagnostic methods. 
sCrea partly satisfies these requirements, but additional information such as height need to be 
considered (as mentioned above). When compared to for example iothalamate clearance as the 
gold standard, sCrea and the Schwartz formula overestimate GFR, especially in renally impaired 
patients.66 Furthermore, sCrea is affected by gender, malnutrition and other diseases such as lupus 
erythematodes, dystrophy, spina bifida and neuromuscular diseases, and correlates with the 
gestational age of newborns.11,35,67–69   
Besides, children with renal dysfunctions, the therapy of pediatric patients suffering from cardiac 
diseases and cancer requires a repetitive evaluation of GFR. As many pharmaceuticals are renally 
eliminated, their dosage needs to be adjusted to renal functioning. Thus, accurate markers of GFR 
are needed.70  
CysC appears to be independent of gender, birth weight, and gestational age.67 Several studies 
already tried to analyze the diagnostic accuracy of CysC and different CysC-based GFR equations, 
but they also proposed further research in large multicenter studies.26,71 To current knowledge, as 
the product of a housekeeping gene, CysC levels are affected by only a few confounders, e.g.,  
high levels of glucocorticoids.14 Still, even in transplant patients with glucocorticoid therapy,  studies 
showed that CysC remains a reliable and accurate marker.60   
Renal dysfunctions require early diagnostic and therapy. Only then, renally eliminated medications 
may adequately be adjusted considering GFR. Reliable endogenous markers such as CysC are 
technically simple and permit fast as well as repetitive diagnostics, whereas GFR-measurements 
with exogenous markers such as inulin or radioisotopes are time-consuming, extensive and 
inappropriate to be used for constant monitoring. 
Among others, Filler stated, "The best approach towards a better formula for worldwide use would 




all endogenous markers, cystatin C appears to be the best surrogate for GFR and it is hoped that 





Renal diseases such as urinary tract infections and congenital anomalies are frequent.64,65 
Therefore, reliable as well as fast and convenient renal diagnostic methods are needed in clinical 
routine. Cystatin C is a suitable and valuable serum marker for renal function and perfusion. 
In infants and adolescents, it is related to age and gender. Nevertheless, as it varies neither 
depending on muscle mass, infectious diseases, shock nor dehydration, it is a more reliable 
parameter in pediatric renal diagnostic than serum creatinine. Furthermore, CysC is constantly 
produced at a stable rate and freely filtered in the glomerulum.14–16  
We derive the following questions and hypotheses from the background information given above: 
How do serum blood levels of CysC vary depending on age and gender? 
In newborns as well as in puberty children’s parameters of CysC alter and depend on gender. 
How does serum CysC compare to sCrea? 
While sCrea varies depending on muscle mass despite age and gender, CysC is a more reliable 
and accurate parameter. 
What factors influence CysC parameters? 
As proposed by earlier studies, CysC serum concentrations are associated with pubertal stage 
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Abstract
Background This study aims to establish age- and gender-specific cystatin C (CysC) reference values for healthy infants,
children, and adolescents and to relate them to pubertal stage, height, weight, and body mass index (BMI).
Methods SerumCysC and creatinine levels of 6217 fasting, morning venous blood samples from 2803 healthy participants of the
LIFE Child study (age 3 months to 18 years) were analyzed by an immunoassay. Recruitment started in 2011; 1636 participants
provided at least one follow-up measurement. Percentiles for CysC were calculated. Age- and gender-related effects of height,
weight, BMI, and puberty status were assessed through linear regression models.
Results Over the first 2 years of life, median CysC levels decrease depending on height (ß = ! 0.010 mg/l/cm, p < 0.001) and
weight (ß = ! 0.033 mg/l/kg, p < 0.001) from 1.06 to 0.88 mg/l for males and from 1.04 to 0.87 mg/l for females. Following the
second year of age, the levels remain stable for eight years. From 11 to 14 years of age, there is an increase of median CysC levels
in males to 0.98 mg/l and a decrease in females to 0.86 mg/l. The change is associated with puberty (ß = 0.105 mg/l/Tanner stage,
p < 0.001 in males and ß = ! 0.093 mg/l/Tanner stage, p < 0.01 in females) and in males with height (ß = 0.003 mg/l/cm,
p < 0.001).
Conclusions CysC levels depend on age, gender, and height, especially during infancy and puberty. We recommend the use of
age- and gender-specific reference values for CysC serum levels for estimating kidney function in clinical practice.
Keywords Children . Adolescents . Cystatin C . Serum creatinine . Reference values
Introduction
Cystatin C (CysC), a cysteine protease inhibitor and low mo-
lecular weight protein, is an endogenous marker for glomeru-
lar filtration rate (GFR). Thus, the kidney function may be
estimated based on CysC [1]. It is produced by all human
nucleated cells at a stable rate, as it is the product of a house-
keeping gene [2]. In contrast, creatinine is produced by the
muscle tissue [3]. Therefore, the currently used GFR estima-
tion formula (0.413 ! height/sCrea(mg/dl)) must consider se-
rum creatinine (sCrea) levels as well as the body height [4]
due to varying body composition (especially muscle mass)
causing inter- and intra-patient variability in sCrea levels
[5–8]. Besides its glomerular filtration, creatinine is also se-
creted by the proximal tubules, leading to an overestimation of
GFR, especially in patients with mild renal impairment [9].
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00467-018-4087-z ) contains supplementary
material, which is available to authorized users.
* Katalin Dittrich
katalin.dittrich@medizin.uni-leipzig.de
1 LIFE Leipzig Research Center for Civilization Diseases, University
of Leipzig, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany
2 Center of Paediatric Research (CPL), University of Leipzig,
04103 Leipzig, Germany
3 Institute for Medical Informatics, Statistics and Epidemiology
(IMISE), University of Leipzig, 04107 Leipzig, Germany
4 Hospital for Children and Adolescents, University of Leipzig,
Liebigstraße 20a, 04103 Leipzig, Germany
5 Institute for Laboratory Medicine, Clinical Chemistry and Molecular
Diagnostics (ILM), University Hospital Leipzig,
04103 Leipzig, Germany
Pediatric Nephrology (2019) 34:449–457
https://doi.org/10.1007/s00467-018-4087-z
CysC, however, is freely filtered in the glomeruli and demon-
strates a high correlation with GFR determined by the gold
standard such as CrEDTA [6, 10–12]. CysC levels are mea-
sured using the rapid and precise particle enhanced turbidi-
metric or nephelometric immunoassays (PETIA and PENIA)
[13, 14].
Previously published data suggest that CysC allows the
assessment of the renal function independently from age and
gender, so a universal reference range of 0.63–1.08 for 1–18-
year-old children was proposed (of note: before 2012/13, dif-
ferent calibrators were used in commercial assays having led
to slightly different reference ranges) [15–18]. Nevertheless,
newborns and infants show higher CysC levels [15–17, 19,
20] and reach steady levels after 1 to 3 years of age [7, 16, 19,
21]. Apparently independent of age and gender, the CysC
levels remain constant up to the age of 14 to 16 years, accord-
ing to some studies even up to adulthood [17]. Yata et al. (n =
1128) as well as Groesbeck et al. (n = 719) published the first
larger pediatric cohort studies showing that CysC levels de-
crease in adolescents aged 15–16 years and are elevated in
males compared to females at that same age [19, 22]. Miliku
et al. found that GFR estimation equations using CysC were
negatively associated with body mass index (BMI) and body
surface area (BSA), but not lean or fat mass percentage [23].
An effect of age, gender, height, and weight on CysC was also
found in adults [24].
This study aims to establish age- and gender-specific CysC
reference values for generally healthy infants, children, and
adolescents. Furthermore, we aim to analyze the effect of pu-
bertal stage, height, weight, and BMI on CysC serum levels.
Methods
Design and study population
This article is structured according to the STROBE Checklist
(Strengthening the Reporting of Observational Studies in
Epidemiology) [25]. As part of the Leipzig Research Centre
for Civilization Diseases (LIFE), the population-based cohort
study LIFE Child has started recruiting urban, primarily
healthy infants, children, and adolescents in Leipzig
(Germany) in 2011. This large population-based cohort has
already been used to establish reference intervals for serum
lipids [26], liver enzymes [27], and iron-related blood param-
eters [28] in children. The examinations take place in the LIFE
Child study center and are carried out by trained medical staff
using highly standardized procedures [29, 30]. LIFE Child
pursues the Declaration of Helsinki [31] and has been ap-
proved by the Ethics Committee of the University of Leipzig
(Reg. No. 264-10-19042010). It is registered under the NCT
trial number 02550236. All data were appropriately
anonymized to comply to the German data protection law.
More information including the recruitment process and re-
petitive examinations can be found in Poulain et al. and
Quante et al. [29, 30].
In this study, all participants of the LIFE Child cohort hav-
ing valid CysC measurements taken between 2011 and 2017
(2926 participants) were included. Children with an age of 0–
16 years can participate in the study and receive invitations for
follow-up examinations until the age of 18 years. Furthermore,
during the first year of life, there are visits at the age of 3, 6, and
12 months. Thus, participants provided data on one to six
follow-up visits.We excluded all participants with renal anom-
alies, nephrolithiasis, or febrile urinary tract infections (118
participants). This information was obtained through
computer-assisted personal interview and sonography diag-
nostic. Furthermore, we identified and excluded four remain-
ing isolated extreme values of CysC (< 0.4mg/l) as well as one
participant with implausible anthropometric data. Thus, a total
of 6217 observations of 1337 females and 1466 males (age 0–
18 years) are included in this study (Fig. 1).
Laboratory assessment
We examined the CysC levels depending on age and gender.
Furthermore, we examined sCrea levels in order to analyze
LIFE Child cohort












Healthy children and adolescents 0 to 18 years
2 803 (6 217)
Fig. 1 Flow chart for the participants of this study. Numbers of
participants (observations). 2926 participants were observed at the age
of 3, 6, and 12 months and thereafter up to once a year. We excluded
participants with renal anomalies, nephrolithiasis, or febrile urinary tract
infections. One participant was excluded due to implausible
anthropometric data. Furthermore, isolated extreme values were
excluded. In summary, 6217 observations of 2803 participants were
available for analysis
450 Pediatr Nephrol (2019) 34:449–457
whether or not our data is comparable to sCrea cohorts of
earlier studies. For CysC and sCrea, morning venous blood
was drawn from each participant by venipuncture using serum
monovettes (Sarstedt AG&Co, Nümbrecht, Germany). The
analyses were performed by the Institute for Laboratory
Medicine, Clinical Chemistry and Molecular Diagnostics
(ILM), University Hospital Leipzig. Serum samples were an-
alyzed on an automated laboratory analyzer, Cobas8000
(Roche Diagnostics, Mannheim Germany), according to man-
ufacturer’s protocol. sCrea was measured with an enzymatic
assay (Roche Diagnostics). Measurement of serum CysC was
performed using the turbidimetric immunoassay (PETIA)
Tina-quant® Cystatin C (Roche Diagnostics). The primary
measurement range is 0.4–8.0 mg/l. Traceability of the meth-
od was standardized against a Roche in-house reference prep-
aration of recombinant human CysC. In April 2015, the Tina-
quant® Cystatin C-assay was advanced to the second genera-
tion (n = 2070 during second versus n = 4401 observations
during the first generation), now standardized against the in-
ternational reference material ERM-DA471/IFCC [30].
Between October 2011 and April 2015, the variation coeffi-
cient of control level 1 varied between 1.3 and 6.4% (mean
3.0%), control level 2 varied between 0.9 and 4.5% (mean
2.0%). The primary measurement range of the Tina-quant®
Cystatin C 2nd generation is 0.4–6.8 mg/l. Comparative mea-
surement of 143 serum samples was performed between Tina-
quant® Cystatin C and Tina-quant® Cystatin C 2nd genera-
tion. Using the MedCalc (MedCalc Software bvba, Belgium),
a Passing-Bablok-regression [32] and Bland-Altman-plot [33]
were calculated (Online Resources 2 and 3). The comparison
showed a good conformity between the first and second gen-
eration of the immunoassay Tina-quant®. The mean bias ac-
counts for 0.03 mg/l. The CysC reference values were not
corrected for this clinically not relevant bias, which is also
comparable to the usual batch effects.
Anthropometric assessment
Height, weight, BMI, and puberty status were taken into ac-
count as potential confounding variables. BMI was calculated
using height and weight measured by instructed and qualified
personnel applying standardized procedures and regularly cal-
ibrated devices (a stadiometer with a measurement accuracy
of 0.1 cm and a Seca 701 scale with a measurement accuracy
of 50 g). The puberty status was examined bymeans of Tanner
stages and assessed by trained staff members [34, 35].
Statistics
The percentiles were estimated applying generalized additive
models for location, shape, and scale as implemented in the
gamlss package combined with a resampling method using
Fig. 2 Cystatin C depends on age in infant and adolescent participants of
the LIFE Child cohort. Solid line = female, dashed line = male
participants. Note that at the age of 12 years, the curves diverge and
show different patterns for males and females thereafter. n = 6217
observations of 2803 participants (0–18 years old)
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the ChildSDS packages as described by Vogel et al. [36, 37].
All statistical analyses and visualization were done using the
R-Software (version 3.3.2) [38]. To examine the influence of
anthropometric measures on CysC levels, we stratified the
data into four age intervals of linear course identified through
visual inspection and local non-parametric regression (infancy
0–2 years, childhood 2–11 years, and adolescence with 11–15
and 15–18 years; see also Fig. 2 created with ggplot) [39].
Linear modeling was favored due to better interpretability.
Hierarchical linear regression analyses (backward deletion)
were applied to determine the effects of the independent var-
iables on CysC levels (lmer-function of the R-package lme4)
[40]. To account for repetitive measurements in follow-up
participants, the subject was added as random effect on the
intercept. T tests were used to compare mean CysC and sCrea
levels of boys and girls (Table 1).
Results
A total of 2803 participants with 6217 observations (Fig. 1
and Table 1) were included. The distributions of pubertal
stages and BMI in the LIFE Child cohort are summarized in
Table 2.
Serum creatinine distribution
The percentiles of sCrea levels for girls and boys are provided
in the Online Resources 1 and 4. First, we evaluated the sCrea
distribution to show that the LIFE Child cohort is comparable
to other studies and, therefore, a representative sample of the
population; sCrea levels rise continuously until the age of
12.5 years (ß-slope = 2.744 !mol/l/a = 0.031 mg/dl/a; a = pe-
riod of 1 year of life) for both boys and girls. At that age,
median sCrea levels are 53 !mol/l = 0.60 mg/dl in girls and
55 !mol/l = 0.62 mg/dl in boys. sCrea levels increase more
rapidly in 12.5- to 18-year-old boys (ß = 5.905 !mol/l/a =
0.067 mg/dl/a). In contrast, the slope (ß) in 12.5- to 18-year-
old girls is constant at around 2.8 !mol/l/a = 0.032 mg/dl/a.
From the age of 13 years, boys exhibit significantly (p < 0.01)
higher sCrea levels than girls.
Serum cystatin C distribution
The distribution of CysC levels in the LIFE Child cohort, the
percentiles and the degree of freedom spread, skewness, loca-
tion, and kurtosis parameters are shown in Fig. 3 and Table 3.
Measurements were elevated for children between the age of
3 months and 18 years. The median CysC serum
Table 1 Numbers of participants, observations, cystatin C (CysC) mean, intercept, and ß-slope of the LIFE Child cohort sorted in age intervals
Infancy Childhood Adolescence All
Age in years 0–2 2–11 11–15 15–18 0–18
Observations, n (%) Males 213 (6) 1712 (52) 1002 (30) 363 (11) 3290 (100)
Females 169 (6) 1433 (49) 895 (31) 430 (15) 2927 (100)
Participants Males 180 903 540 245 1466
Females 146 771 490 278 1337
CysC mean (±SD) in mg/l Males 0.964 (0.149) 0.863 (0.106) 0.940 (0.128) 0.940 (0.117) 0.901 (0.124)
Females 0.950 (0.134) 0.864 (0.105) 0.886 (0.123) 0.813 (0.108) 0.868 (0.117)
t test p > 0.05 p > 0.05 p < 0.001 p < 0.001 p < 0.001
CysC intercept in mg/l Males 1.152 0.846 0.886 0.973 0.860
Females 1.127 0.828 0.933 0.830 0.902
p value p > 0.05 p > 0.05 p < 0.001 p < 0.01 p < 0.001
CysC ß-slope in mg/l/a Males ! 0.159 0.003 0.028 ! 0.033 0.005
Females ! 0.148 0.007 ! 0.023 ! 0.017 ! 0.003
p value p > 0.05 p < 0.05 p < 0.001 p > 0.05 p < 0.001
Height mean (±SD) in cm Males 78.2 (5.77) 124.9 (18.0) 161.4 (11.5) 176.6 (7.1) 138.7 (29.4)
Females 76.3 (5.9) 123.5 (18.3) 159.7 (8.6) 166.5 (6.3) 138.2 (27.9)
Weight mean (±SD) in kg Males 10.19 (1.67) 27.03 (10.91) 54.21 (16.10) 68.47 (16.78) 38.79 (21.59)
Females 9.45 (1.68) 26.51 (11.21) 53.93 (15.27) 62.74 (15.41) 39.20 (21.11)
BMI mean (±SD) in kg/m2 Males 16.6 (1.2) 16.7 (3.0) 20.5 (4.6) 21.9 (4.8) 18.4 (4.3)
Females 16.0 (1.1) 16.7 (3.1) 21.0 (5.0) 22.6 (5.3) 18.8 (4.8)
Age intervals were determined by visual inspection for better interpretation with linear regression models (see Fig. 2). Note that participants may have
undergone various observations that belong to different age intervals. Intercepts and ß-slopes (in mg/l per year of life) were calculated with the lm-
function in R. The intercept represents the mean CysC concentration of the first observations of each age interval
n number of observations, SD standard deviation, BMI body mass index
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concentrations are highest in toddlers (males 1.06 mg/l, fe-
males 1.04 mg/l). They decrease during the first 2 years of
life (ß = ! 0.154 mg/l/a) to slightly but significantly lower
levels (p < 0.001; males: 0.88 mg/l; females: 0.87 mg/l) and
remain constant during childhood until the age of 11 years.
The mean CysC values in girls and boys do not differ signif-
icantly at this age (p > 0.05). While the serum levels of female
adolescents start to decrease at 11 years (ß = ! 0.023 mg/l/a),
those for male adolescents increase (ß = 0.028 mg/l/a). Thus,
at the age of 13 years, CysC levels differ significantly between
males and females (p < 0.001). After reaching 15 years of age
and median levels of 0.97 mg/l in males and 0.84 mg/l in
females, CysC levels of male participants drop again (ß = !
0.033 mg/l/a). In our study cohort, we found that CysC levels
in males and females remained significantly different until the
age of 18 (p < 0.05) with the highest and most significant
difference at the age of 15 years (p < 0.001, mean CysC levels
0.97 mg/l in males and 0.84 mg/l in females).
Among all participants of the LIFE Child cohort, the scale
remains constant as indicated by the sigma-value of 0.12–
0.14 mg/l (Table 3).
Effects of height, weight, BMI, puberty, and age
on cystatin C
To identify potential influential factors for the changes in
CysC levels during infancy and adolescence, we correlated
height, weight, BMI, the Tanner stage, and age with the
CysC concentrations for boys and girls separately. For better
interpretability, linear regression models were applied to four
different intervals of linear course identified through visual
inspection (infancy 0–2 years, childhood 2–11 years, adoles-
cence with 11–15 and 15–18 years; Fig. 2 and Table 1). All
effects are corrected for age (except age itself) and repetitive
measurement in follow-up participants.
In a simple linear regression analysis of the participants
aged 0–2 years, age, height, and weight were shown to be
negatively associated with CysC serum concentrations
(p < 0.001), whereas BMI does not show a significant effect.
In hierarchical regression analyses, CysC levels were nega-
tively correlated with height (ß = ! 0.010 mg/l/cm, p < 0.001)
as well as weight (ß = ! 0.033 mg/l/kg, p < 0.001).
Using stepwise multiple regression models including age,
height, weight, BMI, and Tanner stages CysC levels of male
participants between the age of 11 and 14 years showed a
strong dependency on puberty status (p < 0.001). Even after
adjustment for age, CysC concentrations are significantly
higher in pubertal boys (especially in Tanner stages three
and four with ß " 0.1 mg/l/Tanner stage, p < 0.001), compared
to prepubertal boys. In females at the same age, pubertal stage
is also the strongest predictor of CysC levels (p < 0.001), but
in contrast to males negatively associated with CysC levels
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of CysC concentrations in female adolescents during pubertal
stage two that however is not significantly different from pre-
pubertal CysC concentrations. Weight and BMI show no sig-
nificant effect on CysC levels in adolescents. Height is another
predictor of serum CysC concentrations in pubertal males
(ß = 0.003 mg/l/cm, p < 0.001).
Discussion
This study aimed to propose CysC reference values for healthy
infants, children, and adolescents. We have shown that our
study cohort is a representative sample as sCrea levels are dis-
tributed similar to published results from earlier population-
based studies [16, 41–43]. CysC levels depend on height,
weight, age, and puberty. In newborns, CysC levels are higher
than at later ages. They decrease rapidly during the first 2 years
of life, being negatively associated with height and weight. In
11- to 14-year-old adolescents, the puberty status is the stron-
gestpredictor ofCysCserumconcentrationswith an increaseof
CysC levels in males during early puberty and a decrease in
females during late puberty.
Miliku et al. recently published the results of a study in
healthy 6-year-olds in Rotterdam (Netherlands) using the
same Roche kit for CysC analysis. They did not find signifi-
cant associations of sex and CysC levels nor the eGFR (cal-
culated using CysC levels with the Zappitelli formula) and
sex. Puberty was not considered as they analyzed values of
an age-homogeneous population without newborns and pu-
bertal adolescents [23].
The strength of our study is a broad age range from 0 to
18 years and a large number of observations (n = 6217) of
healthy participants and a standardized assessment. To our
knowledge, LIFE Child is the first European study to present
data from such a large cohort including very young infants
from the age of 3 months. Nevertheless, the results are based
on the social distribution in Leipzig [29, 30]. Therefore, cohort
studies in other geographical areas such as Marmarinos et al.
may be necessary in order to take regional variability into
account [44].
Although earlier studies used different measuring methods
for CysC, the course of the percentiles can be compared: The
given percentiles for CysC levels are concordant to those pro-
posed by earlier studies (0.63–1.08 mg/l) [15–18, 45], but do
not support the thesis of age- and gender-independent refer-
ence values. We found that infants exhibited higher CysC
levels up to the age of 2 years, thereby confirming the results
of other studies such as Andersen et al., Ridefelt et al.,
Randers et al., and Filler et al. [15–17, 19–21]. A possible
explanation is the maturation of kidney function: only the
juxtamedullary glomeruli filter blood in newborns, while all
other nephrons—although already terminally differentiated—
are recruited up to the age of 18–24 months [46, 47]. In 11- to
14-year-old male adolescents, the median CysC concentra-
tions increase to about 0.98 mg/l and thereafter constantly
drop to mean values of 0.88 mg/l. In female adolescents, these
parameters are up to 0.13 mg/dl lower. This partly confirms
the percentiles described by Yata et al. (Japan), Groesbeck
et al. (USA), and Marmarinos et al., who were the first to
conduct larger pediatric cohort studies (n = 1128, 719, and
536, respectively) and showed that CysC levels depend on
age and gender during adolescence [19, 22, 44].
In contrary to the results of Marmarinos et al., the BMI
shows no significant effect on CysC that cannot be explained
by the single variables height or weight. The low correlation
coefficient of r2 = 0.003 (p < 0.001) may explain why no
correlation with lean or fat mass percentage was found by
Miliku et al. in 6-year-old children [23, 44]. The estimation
Fig. 3 Percentiles of cystatin C and its effector variable age for 0- to 18-
year-old children of the LIFE Child cohort. Solid line = 50th percentile,
dotted line = 10th and 90th percentile, dashed line = 2.5th and 97.5th
percentile. P percentile. The percentiles were calculated using the
ChildSDS package [37]. Note that just before the age of 12 years, the
curves diverge and show different patterns for males and females there-
after. n = 6217 observations in 2803 participants
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of the GFR based on sCrea must also consider the body height
(Schwartz et al.) [4] during entire childhood and adolescence.
CysC shows small variance due to height in 0- to 2-year-old
infants (ß = ! 0.010 mg/l/cm) and 11- to 14-year-old male
adolescents (ß = 0.003 mg/l/cm). Thus, body growth may af-
fect CysC concentrations as supposed by its association with
height in infancy and male adolescents during puberty. The
hypothesis is that during body growth more body cells exist
and so more housekeeping protein CysC will be produced.
That leads to a rise in CysC concentrations, which appears
especially applicable to pubertal boys due to a higher body
growth compared to pubertal girls.
We found an increase of CysC levels in male and a decrease
in female adolescents associated with pubertal development.
Table 3 (a) Percentiles of cystatin
C (mg/l) as a function of age
based on the LIFE Child cohort
with 0- to 18-year-old boys. (b)
Percentiles of cystatin C (mg/l) as
a function of age based on the
LIFE Child cohort with 0- to
18-year-old girls
Age n P2.5 P5 P10 P50 P90 P95 P97.5 Mu Sigma Nu Tau
(a)
0 106 0.80 0.84 0.88 1.06 1.24 1.29 1.33 1.06 0.13 0.73 2.12
1 107 0.74 0.77 0.82 0.97 1.14 1.18 1.22 0.97 0.13 0.73 2.09
2 135 0.67 0.70 0.74 0.88 1.02 1.07 1.10 0.88 0.12 0.72 2.05
3 132 0.65 0.68 0.72 0.85 0.98 1.02 1.06 0.85 0.12 0.71 2.00
4 141 0.65 0.68 0.72 0.85 0.98 1.02 1.06 0.85 0.12 0.71 1.96
5 156 0.65 0.68 0.72 0.85 0.99 1.03 1.07 0.85 0.12 0.70 1.90
6 198 0.65 0.69 0.72 0.86 1.00 1.04 1.08 0.86 0.13 0.70 1.85
7 197 0.65 0.68 0.72 0.86 1.00 1.05 1.09 0.86 0.13 0.69 1.79
8 251 0.65 0.69 0.73 0.86 1.01 1.05 1.09 0.86 0.13 0.67 1.74
9 260 0.66 0.69 0.73 0.87 1.01 1.06 1.10 0.87 0.13 0.64 1.69
10 242 0.66 0.70 0.74 0.87 1.02 1.07 1.11 0.87 0.13 0.61 1.65
11 265 0.67 0.71 0.75 0.89 1.03 1.08 1.13 0.89 0.13 0.58 1.61
12 259 0.69 0.73 0.78 0.92 1.07 1.12 1.17 0.92 0.13 0.55 1.59
13 253 0.72 0.76 0.81 0.95 1.11 1.17 1.22 0.95 0.13 0.54 1.59
14 225 0.74 0.78 0.83 0.98 1.14 1.19 1.24 0.98 0.13 0.53 1.61
15 190 0.74 0.78 0.83 0.97 1.13 1.18 1.23 0.97 0.12 0.54 1.65
16 110 0.73 0.77 0.81 0.95 1.10 1.15 1.20 0.95 0.12 0.56 1.69
17 63 0.71 0.74 0.78 0.92 1.06 1.11 1.15 0.92 0.12 0.58 1.76
(b)
0 86 0.80 0.84 0.88 1.04 1.21 1.26 1.30 1.04 0.12 0.59 1.97
1 83 0.74 0.78 0.82 0.96 1.12 1.16 1.20 0.96 0.12 0.61 1.96
2 115 0.67 0.70 0.74 0.87 1.00 1.04 1.08 0.87 0.12 0.63 1.95
3 110 0.64 0.67 0.71 0.83 0.96 1.00 1.03 0.83 0.12 0.65 1.94
4 119 0.65 0.68 0.71 0.84 0.97 1.01 1.04 0.84 0.12 0.67 1.93
5 139 0.66 0.69 0.73 0.86 0.99 1.03 1.06 0.86 0.12 0.69 1.91
6 183 0.67 0.70 0.74 0.86 1.00 1.04 1.07 0.86 0.12 0.70 1.89
7 181 0.67 0.70 0.74 0.87 1.00 1.04 1.07 0.87 0.12 0.70 1.87
8 181 0.68 0.71 0.74 0.87 1.00 1.04 1.08 0.87 0.12 0.70 1.85
9 201 0.68 0.71 0.75 0.88 1.01 1.05 1.09 0.88 0.12 0.70 1.83
10 204 0.68 0.72 0.76 0.89 1.03 1.07 1.11 0.89 0.12 0.68 1.82
11 214 0.69 0.72 0.77 0.91 1.06 1.10 1.14 0.91 0.13 0.66 1.80
12 235 0.68 0.72 0.76 0.91 1.06 1.11 1.16 0.91 0.13 0.63 1.80
13 224 0.66 0.70 0.74 0.89 1.04 1.09 1.14 0.89 0.13 0.58 1.79
14 222 0.64 0.68 0.72 0.86 1.02 1.07 1.11 0.86 0.14 0.53 1.78
15 188 0.63 0.66 0.70 0.84 1.00 1.05 1.09 0.84 0.14 0.48 1.77
16 151 0.62 0.65 0.69 0.83 0.98 1.03 1.07 0.83 0.14 0.42 1.76
17 91 0.61 0.64 0.68 0.81 0.96 1.01 1.05 0.81 0.14 0.36 1.74
The 2.5th, 10th, 90th, and 97.5th percentiles as well as the median are given
n participants, P percentile,Mu location parameter, Sigma spread parameter,Nu skewness parameter, Tau kurtosis
parameter
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There is no explanation so far, why pubertal development has a
reverse effect on CysC serum concentrations inmale and female
adolescents. Similar to the association described by Groesbeck
et al., CysC levels of females showed a peak in Tanner stage two
whereas those of male participants had a peak in Tanner stage
four [22]. At the age of 13 years, the CysC levels start to be
significantly different for males and females. At the age of
15 years, this difference amounts to 0.13 mg/l (15.5% higher
in males compared to females, Table 1) and is similar to that of
sCrea levels at the same age (15.2% higher in males compared
to females). We consider this difference as clinically relevant.
In clinical practice, kidney injury is diagnosed by loss of
estimated GFR or increase in sCrea by 25%, which de-
pends highly on muscle mass [48]. Any known gender-
or age-related changes in parameters of normal kidney
function are necessary for the recognition of renal damage.
This especially applies to formerly unknown patients at the
time of admission for example onto a pediatric intensive
care unit. Therefore, when using CysC parameters, we sug-
gest the use of age- and gender-related CysC reference
values to evaluate renal function in pediatric patients.
Overall, growth rate, serum levels of sexual hormones,
blood glucose, smoking or alcohol consumption may affect
CysC serum concentrations. As we continue our research, we
aim to include the socioeconomic status among the other po-
tential effector variables and confounders in subsequent studies.
Nevertheless, the percentiles of this study suggest that
CysC serum concentration is a stable parameter with narrow
ranges, but with a notable variation in infancy and adoles-
cence related to age, gender, and puberty.
Conclusion
Our study provides CysC reference values derived from a
large pediatric cohort in a homogeneous Caucasian population
(6217 observations of 2803 participants). The results of this
population-based cohort indicate that serum CysC levels do
vary significantly according to age, gender, and pubertal sta-
tus. Therefore, we suggest the use of age and gender-specific
reference ranges for the assessment of kidney function in new-
borns, children, and adolescents.
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The study aimed to check the hypothesis that CysC is related to age and gender in infants and 
adolescents. We were able to show that CysC does not only depend on age and gender, but 
furthermore is associated with pubertal status. These findings oppose the thesis of one uniform 
CysC reference range for infants and adolescents, which only applies to children from the age of 
two up to eleven years. We suggest the application of percentiles for laboratory assessment. The 
percentiles presented in this study (derived from a large Caucasian pediatric cohort with 6 217 
observations) will soon be adopted in clinical routine by the Institute of Laboratory Medicine, Clinical 




The difference of CysC between girls and boys at the age of 15 years amounts to 15.5% and 
therefore is similar to that of sCrea at the same age. Nevertheless, the usage of CysC serum 
concentrations in renal diagnostics has several benefits: First, it appears to be more sensitive for 
renal impairment in patients with a GFR above 60ml/min/1.73m2. Second, CysC shows a stronger 
correlation with gold standard methods and higher diagnostic accuracy as described earlier in this 
dissertation.35–38,41 
Furthermore, compared to sCrea CysC showed a higher correlation with gold standard methods in 
post-transplant patients44,45,47, in diabetic patients with a stable metabolic status49, in patients with 
renal diseases as a result of urine reflux due to a spina bifida11 and in pediatric cancer patients.50 
These findings support the hypothesis of CysC as a reliable and accurate renal parameter in clinical 
routine diagnostics. Finally, CysC equations for estimating the GFR seem to be at least as accurate   
as equations relying on sCrea. Besides, these equations can be applied without additional 
information like height and therefore enable a fast and convenient GFR estimation.51–54 Combined 
formulas considering also height and blood urea nitrogen like the Schwartz formulas yield an even 
better result. These are furthermore the only CysC equations validated for children so far, although 
they are only valid for a GFR between 15 and 75 ml/min/1.73m².⁠9,55 However, the equation 
proposed by Andersen et al. also adjusts for body cell mass and body surface area (besides height), 
and predicts the GFR most accurate.56 
Nevertheless, a major benefit of sCrea needs to be considered: The costs of one laboratory 
assessment at our Institute of Laboratory Medicine in Leipzig is 2€ compared to 15€ for CysC 
according to the medical fee schedule (“Gebührenordnung für Ärzte”).  
 
When additionally examining data of the LIFE Adult cohort (n=254 observations in 228 18- to 26-
year-old adults), from the age of 20 years, we found no significant differences of CysC serum 
concentrations for male and female participants anymore. They approximate one another and 
reach 0.81 mg/l for male and 0.75 mg/l for female 26-year-old adults (Figure 4). These findings 
confirm results presented earlier by Galteau et al..21 Along with the data published by Filler et al. 




age and older). CysC levels as well as CysC formulas in elderly – similarly to children – are more 
sensitive compared to sCrea, although no significant difference in females and males was 
described so far.72,73 Higher serum concentrations of CysC are positively correlated with BMI, 
nephritis, hypertension and leptin, and negatively with neoplasm.74,75 Furthermore, Odden et al. 
found an association of higher CysC with poorer physical function such as slower or not completed 
400-meter walk.76 Therefore, we assume an effect of body composition: as CysC is produced by 
all nucleated cells, a higher body cell mass may result in higher serum concentrations of CysC. 
This hypothesis is also consistent with the fact that the Andersen equation including body cell mass 
and body surface is the most accurate in estimating the GFR as mentioned above.56 Therefore, a 
changing body cell composition due to growth and development may explain the significantly higher 
levels of CysC in newborns, pubertal boys and – to a less extent – pubertal girls. During puberty, 
lutein hormone and follicle stimulating hormone are secreted and stimulate the production of 
testosterone and estrogen and thus body growth and the development of secondary sexual 
characteristics. Especially the body growth is stimulated by a further secretion of thyroxin and 
insulin-like growth factor 1 (IGF1), which may explain the association of CysC and thyroxin found 
by Wiesli et al..61 This applies to girls during early puberty (for pubertal group stratification see 
Table 1) and to an even greater extent to boys during late puberty, as their growth spurt occurs 
later compared to girls. Therefore, girls show a peak of CysC at the age of 12 years, whereas the 
boys’ peak occurs at the age of 14 years. This is in line with Groesbeck et al..32 The higher peak 
for boys may occur because boys grow taller. Besides, higher blood glucose due to increased 
levels of IGF1 may be associated with increased CysC, as it is also found in patients with diabetes 
or glucocorticoid therapy.57,59,60 Overall, an interaction of the hormone system and CysC seems 
obvious. 
 
Limits of this study are data only representing a local,  homogenous Caucasian cohort.77,78 Nevertheless, 
studies in Japan and the U.S. show similar results.27,32 Still, we recommend the examination of CysC serum 
concentrations in children in other geographical areas. Additionally, although we were able to show that CysC 
depends on pubertal stage beyond the effect of age and gender, the underlying physiological and biochemical 




already filtrate blood, whereas the other glomeruli are recruited over the first two years of life.52,79 During puberty, 
growth, thyroxin, testosterone, and insulin-like growth factor 1 among others may affect CysC levels as 
described above. For a better understanding, further research should examine potential associations of CysC 
with hormones (such as follicle stimulating and lutein hormone, testosterone, IGF1, glucocorticoids as well as 
parathyroid hormone), growth velocity and blood glucose.  
Studies already showed that cigarette smoking was associated with higher serum levels of CysC in 
adults.58 Furthermore, patients with proteinuria had elevated urinary levels of CysC62, whereas 
higher levels of CRP and white blood cells and lower serum albumin concentrations were 
associated with elevated serum concentrations of CysC.57–59 Infectious diseases, especially of the 
urinary organ system, may explain these effects. Nevertheless, so far, no studies investigated these 
effects in children. As urinary and renal infections are very frequent64, a reliable and accurate as 
well as fast and non-invasive renal diagnostic with endogenous markers is desirable. CysC seems 
to be more accurate and reliable compared to sCrea. Besides, CysC shows a better correlation 
with the GFR above 60ml/min/1.73m2 than sCrea. Therefore, even the dosage adjustment for 
pharmaceuticals in cardiology or chemotherapeutics in oncological patients may benefit from the 
application of CysC, as it enables a reliable and continued monitoring of the GFR.70  
As proposed by Filler, we calculated percentiles for CysC by assessing a large pool of data.⁠2 Due 
to the large number of observations (n=6 217) of healthy participants as well as the standardized 
assessment, the data and percentiles presented in this study are of high accuracy. To our 
knowledge, LIFE Child is the first European study including very young infants from the age of three 
months as well as children up to 18 years of age. Overall, we strongly recommend the usage of 
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Figure 1. Serum CysC in children aged 3 months to 16 years according to Yata et al..27 
 
The box plot extends from the 25th percentile to the 75th percentile, with the horizontal line at the median, and the 





Figure 2. Serum CysC in male and female children according to Yata et al..27 
 
The box plot extends from the 25th percentile to the 75th percentile, with the horizontal line at the median, and the 
whiskers show the central 95 % of the data for Alfresa (a), Eiken (b), Mitsubishi (c), and Siemens assays (d).27 
 
 IV 
Figure 3. Effector variables of CysC and sCrea according to Stevens et al. 2009.57 
 
Comparison of coefficients of variables predicting log cystatin and log creatinine. Solid diagonal line is the line of identity. 
(…) HTN, hypertension; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean 
arterial blood pressure; WBC, white blood cell count; Na, sodium; K, potassium; Pi, phosphate; Ca, calcium; HCO3, 
bicarbonate; TC, total cholesterol; alb, albumin; gluc, glucose; UUN, urine urea nitrogen; UCR, urine creatinine; UPI, 





































































































































































































PH=1, B=1, <13,5years 















3≤PH≤5, B=4, ≥8years 





PH≥5, TV≥7, ≥9years 
 
Abbreviations: PH = Pubic Hair, B = Breast, TV = Testicular  
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